ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,004.85
-0.11%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.675
0.19%
Brent Oil
83.76
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) ニュース

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KYMR
日付受信時刻ニュースソース見出しコード企業名
2024/05/1423 : 00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
2024/05/0820 : 00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
2024/05/0220 : 00GlobeNewswire Inc.Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
2024/04/2520 : 00GlobeNewswire Inc.Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2NASDAQ:KYMRKymera Therapeutics Inc
2024/04/0820 : 00GlobeNewswire Inc.Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0900 : 00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0508 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0508 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0508 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0507 : 50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/03/0507 : 47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/02/2821 : 00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
2024/02/2806 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/02/2221 : 32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KYMRKymera Therapeutics Inc
2024/02/2221 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
2024/02/2221 : 00GlobeNewswire Inc.Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
2024/02/1521 : 00GlobeNewswire Inc.Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22NASDAQ:KYMRKymera Therapeutics Inc
2024/02/1009 : 47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/02/1006 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
2024/01/3121 : 00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0923 : 17GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0923 : 15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0606 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0606 : 02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
2024/01/0520 : 00GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $275 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0506 : 06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
2024/01/0506 : 01GlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0421 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0421 : 00GlobeNewswire Inc.R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
2024/01/0307 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

最近閲覧した銘柄

NYSE
DIS
Walt Disney
NYSE
AXP
American Express
CCOM
US500
US 500
CCOM
US100
US Tech 100
FX
USDJPY
US Dollar vs Yen
USOTC
ADDYY
Adidas (QX)
NYSE
JPM
JP Morgan Chase
NASDAQ
AAPL
Apple
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
NYSE
CVX
Chevron
CCOM
SILVER
SILVER
AMEX
SPY
SPDR S&P 500
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有